drugset / Trial / NCT00664196
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
NaSingle-groupOpen-labelTreatment
Summary
This study tests the safety and tolerability of autologous anti-PSMA gene-modified T cells (designer T cells) in hormone refractory prostate cancer.
Timeline
- Start
- 2008-04
- Primary completion
- 2017-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gene Modified T Cells | Cell therapy | 1e+10 cells | Intravenous |
| Subject | Gene Modified T Cells | Cell therapy | 1e+11 cells | Intravenous |